683 Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

683 Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-154,960	Closed	-$638K	–	173
2024 Q4	$638K	Buy	+154,960	New	+$611K	0.04%	138
2020 Q2	–	Sell	-52,567	Closed	-$369K	–	149
2020 Q1	$369K	Buy	52,567 +35,900	+215%	+$343K	0.04%	106
2019 Q4	$174K	Sell	16,667 -17,950	-52%	-$190K	0.02%	130
2019 Q3	$386K	Buy	34,617 +16,667	+93%	+$240K	0.04%	102
2019 Q2	$326K	Buy	+17,950	New	+$785K	0.03%	119

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

683 Capital Management's ELDN Position: Q1 2025 in Review

683 Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 154,960 shares — an estimated $638K sold.

683 Capital Management first reported a position in ELDN in Q2 2019 and held it in 5 quarters. The position peaked at $638K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

683 Capital Management reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
683 Capital Management sold 154,960 Eledon Pharmaceuticals shares in Q1 2025, an estimated $638K.
683 Capital Management first reported a position in Eledon Pharmaceuticals in Q2 2019 and held it in 5 quarters.
683 Capital Management's Eledon Pharmaceuticals position peaked at $638K in Q4 2024.
83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.